Glenn Wilkins - Thursday, January 31, 2019 Valneva SE 09:52 AM EST - Valneva SE : Announced positive initial booster data and final Phase 1 data for its leading, unique Lyme disease vaccine candidate VLA15. Valneva SE shares V.VLA are trading unchanged at $0.30.